MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...

In the preceding three months, 6 analysts have released ratings for Bio-Techne TECH, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

Evercore ISI initiated coverage of Bio-Techne (TECH) with an Outperform rating and $75 price target The firm believes that current volatility creates a “nice entry point” for Bio-Techne as ...